Loading organizations...

§ Private Profile · Edmonton
Online database providing structured drug and drug target information for biopharma and drug research, focused on data-driven medicine.
Based in Edmonton, Alberta, DrugBank operates a comprehensive online database of structured drug and drug target information that combines chemical, pharmacological, and pharmaceutical data. The company provides a subscription-based model for biopharma and pharmaceutical enterprises to access premium data and software integrations, alongside a free version for researchers and the general public. The platform currently houses over 160 million data points, serves more than 12 million users annually, and has been cited 26,500 times in academic and scientific literature. In April 2022, the organization secured $9 million in an oversubscribed seed funding round led by Brightspark Ventures, with additional equity participation from Amplitude Ventures and Theodorus. Initially developed as an academic research project at the University of Alberta in 2006, DrugBank was officially commercialized in 2016 by founders Michael Wilson and Craig Knox.
DrugBank has raised $7.4M across 3 funding rounds.
DrugBank has raised $7.4M in total across 3 funding rounds.
DrugBank has raised $7.4M across 3 funding rounds. Most recently, it raised $7.0M Seed in April 2022.
DrugBank is a health‑technology company that maintains the world’s largest curated pharmaceutical knowledgebase and products (APIs, data feeds, and analytics) that power drug discovery, clinical software, and biomedical research worldwide[3][1]. DrugBank combines a machine‑assisted pipeline with expert curation to deliver structured drug, drug‑target, pharmacology and clinical data for researchers, clinicians and enterprise customers[4][5].
High‑Level Overview
For a portfolio‑company style summary of DrugBank as a product/business: DrugBank builds a comprehensive drug knowledgebase and clinical APIs that deliver drug definitions, mechanism, targets, interactions, ADMET, pharmacogenomics and regulatory status to researchers and clinical software developers[3][1]. Its customers include academic labs, biotechs, health‑tech vendors and large pharma, and the product addresses the problem of fragmented, inconsistent drug data by providing a single, curated, machine‑readable source—enabling faster discovery, safer clinical decisioning and more reliable analytics[4][1]. The business shows sustained growth and wide adoption: the knowledgebase averages tens of millions of annual views and is cited in many thousands of academic publications, and the company has commercialized the dataset into enterprise APIs and analytics products since 2015[3][4][2].
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: DrugBank started as an academic dataset and has matured into a trusted, enterprise‑grade pharmaceutical knowledge platform that combines ML with expert curation to serve research, clinical and commercial customers; its ongoing AI and integration push makes it a pivotal infrastructure player in data‑driven drug discovery and clinical software[3][4][5].
DrugBank has raised $7.4M in total across 3 funding rounds.
DrugBank's investors include Brightspark Ventures, Alkeon Capital, BoxOne Ventures, Buckley Ventures, Matt Ocko, Earl Grey Capital, Endeavor Venture Funds, FirstHand Alliance, Goat Capital, GSV Ventures, LAUNCH, Lightspeed Venture Partners.